MedCity News
MAY 30, 2024
Mental health inequities are costing the U.S. $477.5 billion annually. This could rise to $1.3 trillion in 2040 if left unaddressed. The post Mental Health Inequities Could Cost $1.3 Trillion in 2040. How Can the Industry Prevent This? appeared first on MedCity News.
Fierce Pharma
MAY 30, 2024
As various efforts to produce next-generation vaccines in Africa are being carried forward by the likes of the World Health Organization (WHO) and the Bill & Melinda Gates Foundation, BioNTech | Under an expansion of the partners’ existing deal, the Coalition for Epidemic Preparedness Innovations (CEPI) is committing up to $145 million to bolster BioNTech’s efforts to establish vaccine R&D and manufacturing capabilities at the German company’s facility in Kigali, Rwanda.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
MAY 30, 2024
A pending CMS policy could cause havoc for independent kidney care facilities and patients who need life-sustaining treatments. The post Protect Personalized, Independent Kidney Care appeared first on MedCity News.
PharmaVoice
MAY 30, 2024
To lower drug prices, lawmakers are turning to the drug patent system to outlaw some common practices — but a former patent agency director says it’s the wrong way to go.
Advertiser: ZoomInfo
AI adoption is reshaping sales and marketing. But is it delivering real results? We surveyed 1,000+ GTM professionals to find out. The data is clear: AI users report 47% higher productivity and an average of 12 hours saved per week. But leaders say mainstream AI tools still fall short on accuracy and business impact. Download the full report today to see how AI is being used — and where go-to-market professionals think there are gaps and opportunities.
MedCity News
MAY 30, 2024
Plenful has completed a $17 million Series A funding round, bringing its total fundraising amount to date to more than $25 million. The startup offers a software platform that automates the manual and administrative tasks that burden pharmacists and pharmacy technicians. The post Plenful Raises $17M to Help Curb Rising Levels of Pharmacy Burnout appeared first on MedCity News.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
MAY 30, 2024
Hospitals and health systems stand at the forefront of advancing health equity and carry the heavy responsibility of treating illness while promoting wellness and reducing disparities in health outcomes. The post The Vital Role of Hospitals in Tackling Health Inequities appeared first on MedCity News.
Fierce Pharma
MAY 30, 2024
In the span of half a year, Gilead Sciences' Trodelvy has flopped a second phase 3 trial. | Following a high-profile lung cancer setback in January, Gilead said Thursday that Trodelvy also failed to move the needle in a bladder cancer study. The flop threatens the ADC's accelerated approval in the tumor type.
MedCity News
MAY 30, 2024
CinRx Pharma’s most prominent spinout is CinCor Pharma, which was acquired by AstraZeneca last year. The startup creator will apply its new capital toward current programs and to expand to additional areas of unmet medical need. The post CinRx Pharma Corrals $73M to Continue ‘Hub and Spoke’ Model of Startup Formation appeared first on MedCity News.
Fierce Pharma
MAY 30, 2024
In the years since gaining an initial FDA approval for Breyanzi, Bristol Myers Squibb has worked hard to expand the reach of its cell therapy. | In the years since gaining an initial FDA approval for Breyanzi, Bristol Myers Squibb has worked hard to expand the reach of its cell therapy. For the third time in as many months, those efforts have yielded a label expansion at the FDA.
Speaker: Jesse Hunter and Brynn Chadwick
Today’s buyers expect more than generic outreach–they want relevant, personalized interactions that address their specific needs. For sales teams managing hundreds or thousands of prospects, however, delivering this level of personalization without automation is nearly impossible. The key is integrating AI in a way that enhances customer engagement rather than making it feel robotic.
MedCity News
MAY 30, 2024
A group of 24 novel startups were selected to pitch at MedCity News’ INVEST conference in Chicago. Here’s four that VC judges chose as the winners in their respective tracks. The post Here’s Why VC Judges Chose These 4 Startups as INVEST Pitch Perfect Winners appeared first on MedCity News.
Fierce Pharma
MAY 30, 2024
With a target date for FDA approval less than a month away, Sanofi and Regeneron’s megablockbuster Dupixent has gained much attention as it is on the verge of becoming the first biologic to treat c | With Verona Pharmaceuticals' COPD candidate ensifentrine approaching its FDA decision date, GlobalData has referred to it as a “paradigm shift in COPD treatment.
pharmaphorum
MAY 30, 2024
COVID-19 vaccination rates have fallen precipitously in Europe and should be ramped up this autumn so they are at least in line with influenza vaccine uptake.
Fierce Pharma
MAY 30, 2024
With results from a head-to-head study comparing its newer chronic myeloid leukemia (CML) treatment Scemblix to its own standard-of-care tyrosine kinase inhibitor (TKI) Gleevec in newly diagnosed p | Newly diagnosed chronic myeloid leukemia patients on Scemblix achieved a major molecular response rate of 68% at 48 weeks compared to 49% for older drugs, including Novartis' established Gleevec.
Advertiser: ZoomInfo
ZoomInfo customers aren’t just selling — they’re winning. Revenue teams using our Go-To-Market Intelligence platform grew pipeline by 32%, increased deal sizes by 40%, and booked 55% more meetings. Download this report to see what 11,000+ customers say about our Go-To-Market Intelligence platform and how it impacts their bottom line. The data speaks for itself!
PharmaVoice
MAY 30, 2024
By developing ADCs that bind more directly to the target, Mythic Therapeutics believes its technology could deliver a step change for efficacy and safety.
Fierce Pharma
MAY 30, 2024
Gilead Sciences is drawing back the curtain on the Trodelvy lung cancer data that previously caused a 10% slide in the company’s stock price. | Gilead Sciences is drawing back the curtain on the Trodelvy lung cancer data that previously caused a 10% slide in the company’s stock price. In sharing the detailed results, the company is hanging onto a positive sign in a subgroup of patients who have a high unmet medical need.
PharmaTimes
MAY 30, 2024
The first phase of the programme will be in place in hospitals across the UK by March 2025
pharmaphorum
MAY 30, 2024
The US Congress has passed the first-ever federal bill dedicated to ending Parkinson’s disease, modelled on similar legislation for Alzheimer’s enacted in 2011
Speaker: Kevin Burke
AI is reshaping marketing and sales, empowering professionals to work smarter, faster, and more effectively. This webinar will provide a practical introduction to AI, focusing on its current applications, transformative potential, and strategies for successful implementation in your organization. Using real-world examples and actionable insights, we’ll examine how businesses are leveraging AI to increase efficiency, enhance personalization, and drive measurable results.
PharmaTimes
MAY 30, 2024
Affecting the immune system, various forms of SCID are estimated to affect one in 75,000 to 100,000 newborns
pharmaphorum
MAY 30, 2024
The first patient has received a BioNTech colorectal cancer vaccine as part of the NHS Cancer Vaccine Launch Pad (CVLP) 'matchmaker' service
Pharmaceutical Commerce
MAY 30, 2024
The latest news for pharma industry insiders.
pharmaphorum
MAY 30, 2024
Johnson & Johnson's seltorexant hits the mark in a phase 3 trial involving patients with depression and sleep disturbances
Advertiser: ZoomInfo
Incorporating generative AI (gen AI) into your sales process can speed up your wins through improved efficiency, personalized customer interactions, and better informed decision- making. Gen AI is a game changer for busy salespeople and can reduce time-consuming tasks, such as customer research, note-taking, and writing emails, and provide insightful data analysis and recommendations.
Pharmaceutical Technology
MAY 30, 2024
The US FDA approved Teva Pharmaceuticals’ AUSTEDO XR as a once-daily treatment option for tardive dyskinesia and Huntington’s disease chorea.
Pharmaceutical Commerce
MAY 30, 2024
These advancements continue to act as a key driver in helping to boost the security, efficiency, and innovation of global industries, include pharma.
PharmaTech
MAY 30, 2024
A combination of rapid sterility methods with the industry standard compendial method should ensure maximum safety.
European Pharmaceutical Review
MAY 30, 2024
A novel drug delivery method combining proline and metal such as palladium, could enable chemotherapy drugs to be transported in the body via nano-sized cages. Practically, this could enable delivering the structure “more directly” to a tumour, while “shielding healthy cells”. Chemotherapy drugs, antibiotics, as well as antivirals could be transported using this delivery system , the authors theorised.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
pharmaphorum
MAY 30, 2024
In this podcast interview with Dr. Fred Aslan from Artiva Biosciences, explore the potential of NK cells in cell therapy and how they could revolutionise the field of immunotherapy beyond CAR-T therapies.
PharmaTech
MAY 30, 2024
The company’s new division will provide end-to-end integrated discovery services.
pharmaphorum
MAY 30, 2024
The US FDA has given accelerated approval for Eli Lilly’s RET inhibitor as a treatment for various RET-altered paediatric cancers, making it the first drug in the class available for children aged under 12. Retevmo (selpercatinib) can now be used to treat RET-positive thyroid cancers and other solid tumours with the mutation, regardless of their type.
Expert insights. Personalized for you.
337 
Let's personalize your content